Berberine attenuates obesity‐induced insulin resistance by inhibiting miR‐27a secretion

Junda Du,Yu Zhu,Xuehan Yang,Xinru Geng,Yang Xu,Meishuang Zhang,Ming Zhang
DOI: https://doi.org/10.1111/dme.15319
IF: 3.5
2024-05-07
Diabetic Medicine
Abstract:Introduction Berberine (BBR) is an alkaloid found in plants. It has neuroprotective, anti‐inflammatory and lipid‐lowering activity. However, the efficacy of treatment with BBR and the mechanisms through which it acts need further study. Aims This study investigated the therapeutic effects and the mechanism of action of BBR on obesity‐induced insulin resistance in peripheral tissues. Methods High‐fat‐fed C57BL/6J mice and low‐fat‐fed C57BL/6J mice with miR‐27a overexpression were given BBR intervention (100 mg/kg, po), and the oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed. Palmitic acid‐stimulated hypertrophic adipocyte models were treated with BBR (10 μM). Related indicators and protein expression levels were examined. Results The AUCs of the OGTT and the ITT in the BBR intervention group were reduced significantly (p
endocrinology & metabolism
What problem does this paper attempt to address?